1,655 reports of this reaction
3.9% of all ALIROCUMAB reports
#1 most reported adverse reaction
MYALGIA is the #1 most commonly reported adverse reaction for ALIROCUMAB, manufactured by Regeneron Pharmaceuticals, Inc.. There are 1,655 FDA adverse event reports linking ALIROCUMAB to MYALGIA. This represents approximately 3.9% of all 42,209 adverse event reports for this drug.
Patients taking ALIROCUMAB who experience myalgia should discuss this symptom with their healthcare provider to determine whether it may be related to their medication and what alternatives may be available.
MYALGIA is moderately reported among ALIROCUMAB users, representing a notable but not dominant share of adverse events.
In addition to myalgia, the following adverse reactions have been reported for ALIROCUMAB:
The following drugs have also been linked to myalgia in FDA adverse event reports:
MYALGIA has been reported as an adverse event in 1,655 FDA reports for ALIROCUMAB. This does not prove causation, but indicates an association observed in post-market surveillance data.
MYALGIA accounts for approximately 3.9% of all adverse event reports for ALIROCUMAB, making it one of the most commonly reported side effect.
If you experience myalgia while taking ALIROCUMAB, contact your healthcare provider. They can evaluate whether the symptom is related to your medication and discuss potential adjustments to your treatment plan. Do not stop taking prescribed medication without consulting your doctor.